



Weekly Basal Insulin

Clinical Data Overview Phase 3 QWINT Program



1. Events per participant-year of exposure: 2. 95% CI, -0.22 to 0.04; 3. 95% CI, 0.94 to 1.78; 4. 95% CI, -0.22 to 0.061; 5. 95% CI, -0.19 to 0.12; 6. 95% CI, -0.22 to 0; 7. 95% CI, -0.075 to 0.19%.
 ClinicalTrials.gov identifier: NCT05662332. QWINT 1. <https://www.clinicaltrials.gov/ct2/show/NCT05662332>; ClinicalTrials.gov identifier: NCT05362058. QWINT 2. <https://www.clinicaltrials.gov/ct2/show/NCT05362058>; ClinicalTrials.gov identifier: NCT05275400. QWINT 3. <https://www.clinicaltrials.gov/ct2/show/NCT05275400>; ClinicalTrials.gov identifier: NCT05462756. QWINT 4. <https://www.clinicaltrials.gov/ct2/show/NCT05462756>; Eli Lilly and Company. With Once-a-Week Dosing, Insulin Efsitora Alfa Delivers A1C Reduction and Safety Profile Consistent with Daily Insulin. May 16, 2024; Eli Lilly and Company. In a first-of-its-kind fixed dose study, once weekly insulin efsitora alfa leads to A1C reduction similar to daily insulin. September 5, 2024; Bergenstal RM, et al. *Lancet*. 2024;404(10458):1132-1142; Wysham C, et al. *N Engl J Med*. 2024;391(23):2201-2211.
 ERR, estimated ratio rate; ETD, estimated treatment difference.

Clinical Data Overview Phase 3 ONWARDS Program



*Statistically significant. 1 Severe or clinically significant hypoglycaemia events (blood glucose <3 mmol/L) per patient year, included for end of trial/end main phase in-trial. 2 Duration refers to trial main phase.
 ONWARDS 1: QW insulin icodex vs QD insulin glargine U100 both with non-insulin anti-diabetic treatment in insulin-naïve people with T2D; ONWARDS 2: QW insulin icodex vs QD insulin degludec in people with T2D switching from a QD insulin; ONWARDS 3: QW insulin icodex vs QD insulin degludec in insulin-naïve people with T2D; ONWARDS 4: QW insulin icodex vs QD insulin degludec both with mealtime insulin in people with T2D treated with basal and bolus insulin; ONWARDS 5: QW insulin icodex vs QD basal insulin with an app providing dosing recommendation in insulin-naïve people with T2D; ONWARDS 6: QW insulin icodex vs QD insulin degludec both with mealtime insulin in people with T1D
 T1D: Type 1 diabetes; T2D: Type 2 diabetes. Note: Overview refer to primary end-points in main phases of trials